Multidisciplinary Bispecific Care

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, and Amir Ali, PharmD, BCOP, FHOPA, delve into bispecific antibody treatments, focusing on strategies for patient safety and optimizing care in the management of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome.

Related Keywords

Zahra Mahmoudjafari ,Aamir Ali ,Robert Mancini , ,Practice Pearls ,Bispecific Antibodies ,Dlbcl ,Clinical Trials ,Epcorinomab ,Glofitomab ,Approval ,Response Rates ,Duration Of Response ,Progression Free Survival ,Toxicity Profiles ,Crs ,Neurotoxicity ,Trial Design ,Patient Cohorts ,Biospecific Treatments ,Lymphoma Therapy ,Step Up Dosing ,Outpatient Administration ,Patient Education ,Side Effect Management ,Treatment Pathways ,Institutional Preferences ,Decision Making Processes ,Immunotherapy Options ,Side Effect Correlation ,Reatment Adaptation ,Response Assessment ,Tumor Flare Monitoring ,